Detection of bcl-2 translocation in patients with chronic hepatitis C and its possible relation to antiviral therapy : preliminary study
It has been suggested that t(14;18) translocation of bcl-2 to the immunoglobulin heavy chain (IgH) locus may contribute to the pathogenesis of lymphoproliferative disorders (LPD) related to hepatitis C virus (HCV) infection. The present study aimed to assess the prevalence of bcl-2 translocation in...
Gespeichert in:
Veröffentlicht in: | Journal of Egyptian National Cancer Institute 2007-09, Vol.19 (3), p.211-218 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | It has been suggested that t(14;18) translocation of
bcl-2 to the immunoglobulin heavy chain (IgH) locus may
contribute to the pathogenesis of lymphoproliferative
disorders (LPD) related to hepatitis C virus (HCV) infection.
The present study aimed to assess the prevalence of
bcl-2 translocation in Egyptian chronic HCV patients and
to investigate the effect of combination antiviral therapy
of interferon a and ribavirin on t(14;18). Fifty five chronic
HCV patients were studied for the prevalence of t(14;18).
These patients were classified into 2 groups, 33 non treated
HCV patients and 22 treated HCV patients with antiviral
therapy as well as control group of age and sex matched
individuals. The bcl-2/IgH rearrangement was detected
in peripheral blood mononuclear cells (PBMCs) by nested
polymerase chain reaction. All patients have undergone
HCV viral determination by real time PCR. Bcl-2/IgH
translocation was detected in 21 (38.2%) of all 55 chronically
infected HCV patients. Considering all patients with
chronic HCV-infection, bcl-2 rearrangement was slightly
more frequent in the non treated group than in those who
underwent treatment with interferon plus ribavirin but the
difference was not statistically significant, although treated
patients showed biochemical and virologic response at
the end of 6 months of antiviral therapy. In conclusion,
t(14;18) in PBMCs is a frequent finding in chronic HCV
infection. |
---|---|
ISSN: | 1110-0362 1687-9996 |